Metabolic Messengers: ceramides.
Journal
Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
28
06
2019
accepted:
24
09
2019
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
20
1
2021
Statut:
ppublish
Résumé
Ceramides are products of metabolism that accumulate in individuals with obesity or dyslipidaemia and alter cellular processes in response to fuel surplus. Their actions, when prolonged, elicit the tissue dysfunction that underlies diabetes and heart disease. Here, we review the history of research on these enigmatic molecules, exploring their discovery and mechanisms of action, the evolutionary pressures that have given them their unique attributes and the potential of ceramide-reduction therapies as treatments for cardiometabolic disease.
Identifiants
pubmed: 32694860
doi: 10.1038/s42255-019-0134-8
pii: 10.1038/s42255-019-0134-8
pmc: PMC7549391
mid: NIHMS1634241
doi:
Substances chimiques
Ceramides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1058Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK115824
Pays : United States
Organisme : NIDDK NIH HHS
ID : R43 DK116450
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020579
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK122001
Pays : United States
Organisme : NIDDK NIH HHS
ID : R44 DK116450
Pays : United States
Références
Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).
pubmed: 17339025
Chaurasia, B. et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 365, 386–392 (2019).
pubmed: 31273070
Raichur, S. et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687–695 (2014).
pubmed: 25295789
Kurek, K. et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 34, 1074–1083 (2014).
pubmed: 24106929
Correnti, J. M., Juskeviciute, E., Swarup, A. & Hoek, J. B. Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G959–G973 (2014).
pubmed: 24742988
pmcid: 4042116
Kasumov, T. et al. Ceramide as a mediator of non-alcoholic fatty liver disease and associated atherosclerosis. PLoS One 10, e0126910 (2015).
pubmed: 25993337
pmcid: 4439060
Chen, T. C. et al. An ANGPTL4-ceramide-PKCzeta axis mediates chronic glucocorticoid exposure-induced hepatic steatosis and hypertriglyceridemia in mice. J. Biol. Chem. 294, 9213–9224 (2019).
pubmed: 31053639
Dekker, M. J. et al. Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction. Atherosclerosis 228, 98–109 (2013).
pubmed: 23466071
Park, T. S., Rosebury, W., Kindt, E. K., Kowala, M. C. & Panek, R. L. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol. Res. 58, 45–51 (2008).
pubmed: 18611440
Glaros, E. N. et al. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J. Lipid Res. 49, 324–331 (2008).
pubmed: 17978313
Glaros, E. N. et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem. Pharmacol. 73, 1340–1346 (2007).
pubmed: 17239824
Park, T. S. et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189, 264–272 (2006).
pubmed: 16458317
Hojjati, M. R. et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280, 10284–10289 (2005).
pubmed: 15590644
Park, T. S. et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110, 3465–3471 (2004).
pubmed: 15545514
Park, T. S. et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49, 2101–2112 (2008).
pubmed: 18515784
pmcid: 2533410
Ji, R. et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight 2, 82922 (2017).
pubmed: 28469091
Holland, W. L. et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J. Clin. Invest. 121, 1858–1870 (2011).
pubmed: 21490391
pmcid: 3083776
Vasiliauskaité-Brooks, I. et al. Structural insights into adiponectin receptors suggest ceramidase activity. Nature 544, 120–123 (2017).
pubmed: 28329765
pmcid: 5595237
Westra, B. Ceramides, Plasma [A Test in Focus]. Mayo Clinic Laboratories https://news.mayomedicallaboratories.com/2016/07/28/ceramides-plasma-a-test-in-focus/ (2016).
Summers, S. A. Could ceramides become the new cholesterol? Cell Metab. 27, 276–280 (2018).
pubmed: 29307517
Merrill, A. H. Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277, 25843–25846 (2002).
pubmed: 12011104
Park, J. W., Park, W. J. & Futerman, A. H. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim. Biophys. Acta 1841, 671–681 (2014).
pubmed: 24021978
Hannun, Y. A. & Obeid, L. M. Ceramide: an intracellular signal for apoptosis. Trends Biochem. Sci. 20, 73–77 (1995).
pubmed: 7701566
Kolesnick, R. Ceramide: a novel second messenger. Trends Cell Biol. 2, 232–236 (1992).
pubmed: 14731480
Obeid, L. M., Linardic, C. M., Karolak, L. A. & Hannun, Y. A. Programmed cell death induced by ceramide. Science 259, 1769–1771 (1993).
pubmed: 8456305
Shimabukuro, M. et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats: role of serine palmitoyltransferase overexpression. J. Biol. Chem. 273, 32487–32490 (1998).
pubmed: 9829981
Shimabukuro, M., Zhou, Y. T., Levi, M. & Unger, R. H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA 95, 2498–2502 (1998).
pubmed: 9482914
Summers, S. A., Garza, L. A., Zhou, H. & Birnbaum, M. J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457–5464 (1998).
pubmed: 9710629
pmcid: 109130
Wang, C. N., O’Brien, L. & Brindley, D. N. Effects of cell-permeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 47, 24–31 (1998).
pubmed: 9421370
Zhou, H., Summers, S. A., Birnbaum, M. J. & Pittman, R. N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem. 273, 16568–16575 (1998).
pubmed: 9632728
Jay, A. G. & Hamilton, J. A. The enigmatic membrane fatty acid transporter CD36: new insights into fatty acid binding and their effects on uptake of oxidized LDL. Prostaglandins Leukot. Essent. Fat. Acids 138, 64–70 (2018).
Xu, S., Jay, A., Brunaldi, K., Huang, N. & Hamilton, J. A. CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. Biochemistry 52, 7254–7261 (2013).
pubmed: 24090054
Jiang, C. et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386–402 (2015).
pubmed: 25500885
Hyde, R., Hajduch, E., Powell, D. J., Taylor, P. M. & Hundal, H. S. Ceramide down-regulates System A amino acid transport and protein synthesis in rat skeletal muscle cells. FASEB J. 19, 461–463 (2005).
pubmed: 15611152
Finicle, B. T. et al. Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6. J. Cell Sci. 131, jcs213314 (2018).
pubmed: 29848659
pmcid: 6031383
Guenther, G. G. et al. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc. Natl Acad. Sci. USA 105, 17402–17407 (2008).
pubmed: 18981422
Edinger, A. L. Starvation in the midst of plenty: making sense of ceramide-induced autophagy by analysing nutrient transporter expression. Biochem. Soc. Trans. 37, 253–258 (2009).
pubmed: 19143642
Cowart, L. A. & Obeid, L. M. Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function. Biochim. Biophys. Acta 1771, 421–431 (2007).
pubmed: 16997623
Chung, N., Mao, C., Heitman, J., Hannun, Y. A. & Obeid, L. M. Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae. J. Biol. Chem. 276, 35614–35621 (2001).
pubmed: 11468289
Kogot-Levin, A. & Saada, A. Ceramide and the mitochondrial respiratory chain. Biochimie 100, 88–94 (2014).
pubmed: 23933096
Zigdon, H. et al. Ablation of ceramide synthase 2 causes chronic oxidative stress due to disruption of the mitochondrial respiratory chain. J. Biol. Chem. 288, 4947–4956 (2013).
pubmed: 23283968
pmcid: 3576098
Turpin, S. M. et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678–686 (2014).
pubmed: 25295788
Hajduch, E. et al. Targeting of PKCzeta and PKB to caveolin-enriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramide. Biochem. J. 410, 369–379 (2008).
pubmed: 17983354
Powell, D. J., Hajduch, E., Kular, G. & Hundal, H. S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell. Biol. 23, 7794–7808 (2003).
pubmed: 14560023
pmcid: 207567
Bourbon, N. A., Sandirasegarane, L. & Kester, M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J. Biol. Chem. 277, 3286–3292 (2002).
pubmed: 11723139
Xia, J. Y. et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22, 266–278 (2015).
pubmed: 26190650
pmcid: 4527941
Taniguchi, C. M. et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3, 343–353 (2006).
pubmed: 16679292
Blouin, C. M. et al. Plasma membrane subdomain compartmentalization contributes to distinct mechanisms of ceramide action on insulin signaling. Diabetes 59, 600–610 (2010).
pubmed: 19959757
Stratford, S., Hoehn, K. L., Liu, F. & Summers, S. A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279, 36608–36615 (2004).
pubmed: 15220355
Chavez, J. A. & Summers, S. A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys. 419, 101–109 (2003).
pubmed: 14592453
Russo, S. B. et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 122, 3919–3930 (2012).
pubmed: 23023704
pmcid: 3484448
Westermann, B. Bioenergetic role of mitochondrial fusion and fission. Biochim. Biophys. Acta 1817, 1833–1838 (2012).
pubmed: 22409868
Hammerschmidt, P. et al. CerS6-derived sphingolipids interact with MFF and promote mitochondrial fragmentation in obesity. Cell 177, 1536–1552.e1523 (2019).
pubmed: 31150623
Smith, M. E. et al. Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle. Biochem. J. 456, 427–439 (2013).
pubmed: 24073738
Ehehalt, R. et al. Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts). BMC Cell Biol. 9, 45 (2008).
pubmed: 18700980
pmcid: 2533316
Pohl, J. et al. Long-chain fatty acid uptake into adipocytes depends on lipid raft function. Biochemistry 43, 4179–4187 (2004).
pubmed: 15065861
Covey, S. D. et al. Cholesterol depletion inhibits fatty acid uptake without affecting CD36 or caveolin-1 distribution in adipocytes. Biochem. Biophys. Res. Commun. 355, 67–71 (2007).
pubmed: 17291449
Chaurasia, B., Holland, W. L. & Summers, S. A. Does this Schlank make me look fat? Trends Endocrinol. Metab. 29, 597–599 (2018).
pubmed: 29685851
pmcid: 6098725
Sociale, M. et al. Ceramide synthase Schlank is a transcriptional regulator adapting gene expression to energy requirements. Cell Rep. 22, 967–978 (2018).
pubmed: 29386138
Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68, 280–295 (2018).
pubmed: 29154964
Alkhouri, N., Dixon, L. J. & Feldstein, A. E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3, 445–451 (2009).
pubmed: 19673631
pmcid: 2775708
Hoekstra, D. Ceramide-mediated apoptosis of hepatocytes in vivo: a matter of the nucleus? J. Hepatol. 31, 161–164 (1999).
pubmed: 10424298
Nikolova-Karakashian, M. Sphingolipids at the crossroads of NAFLD and senescence. Adv. Cancer Res. 140, 155–190 (2018).
pubmed: 30060808
Garcia-Ruiz, C., Marí, M., Colell, A., Morales, A. & Fernandez-Checa, J. C. Metabolic therapy: lessons from liver diseases. Curr. Pharm. Des. 17, 3933–3944 (2011).
pubmed: 21933146
Brown, M. S. & Goldstein, J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7, 95–96 (2008).
pubmed: 18249166
Ussher, J. R. et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59, 2453–2464 (2010).
pubmed: 20522596
pmcid: 3279530
Yang, G. et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297, E211–E224 (2009).
pubmed: 19435851
pmcid: 2711669
Blachnio-Zabielska, A. U. et al. Inhibition of ceramide de novo synthesis affects adipocytokine secretion and improves systemic and adipose tissue insulin sensitivity. Int. J. Mol. Sci. 19, E3995 (2018).
pubmed: 30545025
Zhang, Q. J. et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 61, 1848–1859 (2012).
pubmed: 22586587
pmcid: 3379648
Chaurasia, B. et al. Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab. 24, 820–834 (2016).
pubmed: 27818258
Turpin-Nolan, S. M. et al. CerS1-derived C18:0 ceramide in skeletal muscle promotes obesity-induced insulin resistance. Cell Rep. 26, 1–10.e17 (2019).
pubmed: 30605666
Stancevic, B. & Kolesnick, R. Ceramide-rich platforms in transmembrane signaling. FEBS Lett. 584, 1728–1740 (2010).
pubmed: 20178791
pmcid: 4440589
Mantovani, A. et al. Association of plasma ceramides with myocardial perfusion in patients with coronary artery disease undergoing stress myocardial perfusion scintigraphy. Arterioscler. Thromb. Vasc. Biol. 38, 2854–2861 (2018).
pubmed: 30571175
Anroedh, S. et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J. Lipid Res. 59, 1729–1737 (2018).
pubmed: 29858423
pmcid: 6121931
Hilvo, M. et al. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. Atherosclerosis 269, 159–165 (2018).
pubmed: 29366988
Havulinna, A. S. et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 Cohort. Arterioscler. Thromb. Vasc. Biol. 36, 2424–2430 (2016).
pubmed: 27765765
Laaksonen, R. et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. 37, 1967–1976 (2016).
pubmed: 27125947
pmcid: 4929378
Tarasov, K. et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J. Clin. Endocrinol. Metab. 99, E45–E52 (2014).
pubmed: 24243630
Cheng, J. M. et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis 243, 560–566 (2015).
pubmed: 26523994
Yu, J. et al. Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can. J. Cardiol. 31, 357–363 (2015).
pubmed: 25746025
Pan, W. et al. Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron. Artery Dis. 25, 230–235 (2014).
pubmed: 24589572
Lemaitre, R. N. et al. Circulating sphingolipids, insulin, HOMA-IR and HOMA-B: the Strong Heart Family Study. Diabetes 67, 1663–1672 (2018).
pubmed: 29588286
pmcid: 6054436
Jensen, P. N. et al. Circulating sphingolipids, fasting glucose, and impaired fasting glucose: the Strong Heart Family Study. EBioMedicine 41, 44–49 (2019).
pubmed: 30594552
Lemaitre, R. N. et al. Circulating sphingolipids, insulin, HOMA-IR, and HOMA-b: the Strong Heart Family Study. Diabetes 67, 1663–1672 (2018).
pubmed: 29588286
pmcid: 6054436
Bergman, B. C. et al. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am. J. Physiol. Endocrinol. Metab. 309, E398–E408 (2015).
pubmed: 26126684
pmcid: 4537923
Haus, J. M. et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337–343 (2009).
pubmed: 19008343
pmcid: 2628606
Boon, J. et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 62, 401–410 (2013).
pubmed: 23139352
pmcid: 3554351
Lopez, X., Goldfine, A. B., Holland, W. L., Gordillo, R. & Scherer, P. E. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J. Pediatr. Endocrinol. Metab. 26, 995–998 (2013).
pubmed: 23612696
Brozinick, J. T. et al. Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int. J. Obes. (Lond.) 37, 1064–1070 (2013).
Warshauer, J. T. et al. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. Diabetes Metab. Res. Rev. 31, 734–744 (2015).
pubmed: 25959529
Wigger, L. et al. Plasma dihydroceramides are diabetes susceptibility biomarker candidates in mice and humans. Cell Rep. 18, 2269–2279 (2017).
pubmed: 28249170
Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167–1175 (2016).
pubmed: 26780287
Luukkonen, P. K. et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care 41, 1732–1739 (2018).
pubmed: 29844096
Amati, F. et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes 60, 2588–2597 (2011).
pubmed: 21873552
pmcid: 3178290
Coen, P. M. et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 59, 80–88 (2010).
pubmed: 19833891
Coen, P. M. & Goodpaster, B. H. Role of intramyocelluar lipids in human health. Trends Endocrinol. Metab. 23, 391–398 (2012).
pubmed: 22721584
pmcid: 4908975
Coen, P. M. et al. Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severeobesity. Obes. (Silver Spring) 21, 2362–2371 (2013).
Dubé, J. J. et al. Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 54, 1147–1156 (2011).
pubmed: 21327867
pmcid: 3804898
Adams, J. M. II et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25–31 (2004).
pubmed: 14693694
Othman, A. et al. Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. BMJ Open Diabetes Res. Care 3, e000073 (2015).
pubmed: 25815206
pmcid: 4368929
Othman, A. et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 55, 421–431 (2012).
pubmed: 22124606
Mwinyi, J. et al. Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. PLoS One 12, e0175776 (2017).
pubmed: 28472035
pmcid: 5417440
Khan, A. & Hornemann, T. Correlation of the plasma sphingoid base profile with results from oral glucose tolerance tests in gestational diabetes mellitus. EXCLI J. 16, 497–509 (2017).
pubmed: 28694753
pmcid: 5491909
Bertea, M. et al. Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 9, 84 (2010).
pubmed: 20712864
pmcid: 2931514
Russo, S. B., Tidhar, R., Futerman, A. H. & Cowart, L. A. Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties. J. Biol. Chem. 288, 13397–13409 (2013).
pubmed: 23530041
pmcid: 3650378
Skovbro, M. et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 51, 1253–1260 (2008).
pubmed: 18458871
Petersen, M. C. & Shulman, G. I. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol. Sci. 38, 649–665 (2017).
pubmed: 28551355
pmcid: 5499157
Itani, S. I., Ruderman, N. B., Schmieder, F. & Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-alpha. Diabetes 51, 2005–2011 (2002).
pubmed: 12086926
Szendroedi, J. et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl Acad. Sci. USA 111, 9597–9602 (2014).
pubmed: 24979806
Nowotny, B. et al. Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans. Diabetes 62, 2240–2248 (2013).
pubmed: 23454694
pmcid: 3712035
Petersen, M. C. & Jurczak, M. J. CrossTalk opposing view: intramyocellular ceramide accumulation does not modulate insulin resistance. J. Physiol. (Lond.) 594, 3171–3174 (2016).
Summers, S. A. & Goodpaster, B. H. CrossTalk proposal: intramyocellular ceramide accumulation does modulate insulin resistance. J. Physiol. (Lond.) 594, 3167–3170 (2016).
Holland, W. L. & Scherer, P. E. PAQRs: a counteracting force to ceramides? Mol. Pharmacol. 75, 740–743 (2009).
pubmed: 19158359
pmcid: 2684919
Blachnio-Zabielska, A. U., Koutsari, C., Tchkonia, T. & Jensen, M. D. Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance. Obes. (Silver Spring) 20, 2341–2347 (2012).
de Mello, V. D. et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52, 2612–2615 (2009).
pubmed: 19669729
Sims, K. et al. Kdo2-lipid A, a TLR4-specific agonist, induces de novo sphingolipid biosynthesis in RAW264.7 macrophages, which is essential for induction of autophagy. J. Biol. Chem. 285, 38568–38579 (2010).
pubmed: 20876532
pmcid: 2992289
Schilling, J. D. et al. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 288, 2923–2932 (2013).
pubmed: 23250746
Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015–3025 (2006).
pubmed: 17053832
pmcid: 1616196
Kim, J. K. et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108, 437–446 (2001).
pubmed: 11489937
pmcid: 209353
Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11, 183–190 (2005).
pubmed: 15685173
pmcid: 1440292
Majumdar, I. & Mastrandrea, L. D. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 41, 442–449 (2012).
pubmed: 22228496
Gonzalez, F. J., Jiang, C., Xie, C. & Patterson, A. D. Intestinal farnesoid X receptor signalling modulates metabolic disease. Dig. Dis. 35, 178–184 (2017).
pubmed: 28249275
pmcid: 6595218
Xie, C. et al. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66, 613–626 (2017).
pubmed: 28223344
Gonzalez, F. J., Jiang, C. & Patterson, A. D. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 151, 845–859 (2016).
pubmed: 27639801
pmcid: 5159222
Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
pubmed: 26670557
pmcid: 4682112
Curran, J. E. et al. 63rd Annual Meeting Am. Soc. Hum. Genet. https://www.ashg.org/2013meeting/abstracts/fulltext/f130122450.htm (2013).